QMS-GPP Planning According to ISO:9000


Quality management is the practice of ensuring consistency in products and services throughout your organization. A Quality Management System (QMS) helps your cannabis business provide customers with the best you can offer while mitigating risks using tools that support Health Canada’s Good Production Practices.

A Quality Management System-Good Production Practices Plan provides an overview of the quality management system that an organization has in place. Although there are many standards in the world, ISO:9000 is one of the most respected. And according to ISO:9000 standards, the plan must contain the following.

Quality Policy (ISO:9000 clause 5.2): A quality statement can be derived from a mission statement and/or vision statement, but should explain the organization’s commitment to quality

Quality Objectives (ISO:9000 clause 6.2): These can be the organization’s objectives from a business plan, again, as long as they contain a commitment to quality

Criteria for Evaluation and Selection of Suppliers: As quality management and good production practices are often dependent on supplies and equipment that come from other organizations, organizations need to have a criteria in place for evaluating their suppliers to ensure that they select suppliers that meet QMS and GPP standards

Scope of the QMS: This is a list of all SOPs with brief descriptions/purposes

Quality Product Statement

ISO:9000 requires your organization’s quality policy to be appropriate to your organization’s strategic direction and operational direction (context).

Your organization must understand and identify all the influences that affect its business and ensure that the strategy and direction takes quality into consideration. Your organization will need to review its current quality policy regularly to ensure that any changes in context, interested parties or other requirements are reflected, and to determine whether your organization’s objectives are affected. (ISO 9001:2015 – 6.2.1a.)

Following is an example.

Company ABC produces cannabis products for distribution in Canada according to the regulations in the Cannabis Act. The Company has developed its production system through experience and its aim is to achieve a high standard of production and products to its customers.

It is the policy of Company ABC to provide the customer with goods to the agreed requirement in accordance with the details and price.

The Directors, Management and Staff are responsible for Quality Control through the Quality Management System seeking improvement by constant review, with suppliers and sub-contractors being encouraged to co-operate. The Company is committed to achieving customer satisfaction by the use of quality procedures which will be operated to meet or exceed the requirements of [the Cannabis Act and/or ISO 9001 or other quality system].

Quality Objectives

The quality objectives should act as a driver for continual improvement. To meet quality standards, your organization will be required to ensure that you continually improve products and services to meet customer requirements and to measure effectiveness of the processes responsible.

Following is an example.

Company ABC strives to be the best provider of cannabis products in Canada. Through the use of this guiding principle, everyone in Company ABC is accountable for fully satisfying our customers and authorities by meeting or exceeding their needs and expectations with best-in-class production practices. Our goal is 100% customer satisfaction and compliance 100% of the time.

Our Quality Policy is defined and strongly driven by the following objectives:

1. Meet all compliance requirements for all levels of governments and regulatory agencies

2. Build a mutually profitable relationship with our customers, ensuring their long-term success, through the understanding of their needs and the needs of their customers as well

3. Achieve our commitments for quality, cost, and schedule

4. Use of best preventive practices at all levels and ensure reliable risk management

5. Drive continual improvement and innovation based upon efficient business processes, well-defined measurements, best practices, and customer surveys

6. Develop staff competencies, creativity, empowerment and accountability through appropriate development programs and show strong management involvement and commitment

Evaluation and Selection of Suppliers

Supplier evaluation is a system for recording and ranking the performance of a supplier in terms of a variety of criteria and is a must in ISO:9000. A process of vendor rating is essential to effective purchasing. While there is no one right system for supplier evaluation and selection process, the overall objective is to reduce risk and maximize overall value to the purchaser.


There are eight common supplier selection criteria:
1. Cost
2. Quality & Safety
3. Delivery
4. Service
5. Social Responsibility
6. Convenience/Simplicity
7. Risk
8. Agility

In the cannabis industry, you should also add a commitment to meeting compliance and/or helping their customers meet compliance.


There are many other methods of evaluation, and the organization should determine which is the best for its use.

Categorical systems typically use excellent, good, average, poor and so on.

Weighted systems rate on a scale from 1 to 10 or out of 100.

Hierarchical systems give values in relation to each item’s importance. The most important item is given the highest value.


Of course, a quality management system and good production practices plan is only as good as the processes that support it. Creating standard operating procedures and ensuring that all personnel follow them will give you the best chance of success.

For more information about ISO:9000 visit: ISO – ISO 9000 family — Quality management

For information on how AirMed helps you meet compliance, visit our Compliance page.

If you’d like to learn about our quality management and GPP offerings or discuss your specific needs, please give us a call at 1-877-313-2442 or use one of the contact forms.

GS1 Trend Report 2023/2024

Selling any product, including cannabis, starts with a unique identification number from GS1. The GS1 (Global Standards 1) organization is a neutral, global collaboration platform that brings industry leaders, government, regulators, academia, and associations together to develop standards-based solutions to address the challenges of data exchange.

GS1—which has local Member Organisations in 116 countries, over two million user companies and 10 billion transactions every day—helps ensure that there is a common language of business across the globe. GS1 manages the Global Trade Item Number or GTIN, which identifies companies and their products and services using barcode data.

“Trend Research 2023-2024” is a report published recently by GS1 that discusses the top business trends in the world. Topics include data privacy, supply chain digitalisation, traceability and new technologies.

“A cornerstone of any digital transformation are the concepts that are core to the GS1 system: globally unique identification, a common data language, a commitment to interoperability and a firm belief that business value achieved through data sharing is amplified through the use of standards.”

Alberta Loosens Cannabis Regulations

Alberta is changing provincial cannabis regulations to “give retailers more time to focus on their business, while ensuring health, safety, and security remain a top priority.”

The Alberta government made the announcement in December 2023 in a media release titled, “Reducing red tape for cannabis retailers.”

On January 31, 2024, the following improvements to the Gaming, Liquor and Cannabis Regulation will come into force:

  • Licensed cannabis retailers can operate temporary sales locations at adults-only events like trade shows and festivals.
  • Cannabis retailers can keep their products in locked display cases when the store is closed rather than moving everything into a secured storage room at the close of every business day.
  • Restrictions are removed on sales and transfers between cannabis retailers and to further allow Alberta Gaming, Liquor and Cannabis to establish resale markup limits.

Dale Nally, Minister of Service Alberta and Red Tape Reduction, was quoted as saying, “We’ve been looking at the cannabis market to determine what’s working, what needs to be improved, and what’s redundant or unnecessary while protecting public health and safety. These changes are the result of our latest work to help curb the illegal cannabis industry and continue providing choices Albertans can trust.”

Stratcann, one of Canada’s cannabis news platforms, reported, “…a media representative for the AGLC tells StratCann that the ‘policies and processes to support cannabis licensees who are interested in operating temporary sales locations are in development and will be shared with cannabis stakeholders prior to the implementation date.’”

The CBC reported, “In Edmonton and Calgary, city bylaws already allow smoking or vaping cannabis at outdoor festivals and public events, but only in designated areas. And in those cases, selling cannabis on site isn’t allowed… The changes will allow licensed cannabis retailers to set up temporary sales at adults-only events, like trade shows and festivals. They also ease some of the restrictions around how store owners can transfer product between different locations and lift the requirement to store product in a secure area off the shop floor while the store is closed.”

Cannabis in Alberta is regulated by the Alberta Gaming, Liquor and Cannabis (AGLC) ministry.

Important Cannabis Council of Canada Excise Tax Request

Cannabis Council of Canada surveyed licensed producers and has released their findings in a report that you can access here: https://cannabis-council.ca/files/advocacy/C3-Excise-survey.pdf

But that’s not the end of this story. In fact, it’s just the beginning. CCC announced that after bringing their excise tax survey results to Ottawa during the Grass on the Hill Summit last month, the Department of Finance wants to learn more.

“The Department of Finance would like to get a deeper understanding of how excise tax impacts License Holders’ financial positions, and how different rate models can help the long-term viability of our sector.”

This is where you come in.

CCC is asking Health Canada License Holders who pay excise tax to provide the Canadian government with a confidential look at their financials for 2022. Note that deadline to respond: November 30, 2023.

For details and to access the CCC excise model spreadsheet use the contact information below before the November 30 deadline!

Email CCC directly at hello @ cannabis-council.ca

If the email link doesn’t work, visit the Cannabis Council of Canada website for contact information: https://cannabis-council.ca/

MJBizDaily Publishes Series on Government Funding for Canadian Producers

In the first article of a series, MJBiz Daily reported “More Canadian cannabis companies are tapping government funding sources to finance research and other projects as private-sector capital has become harder to come by.”

That article, written by MJBiz Daily International Editor Matt Lamers, was published September 28, 2023 with the title “Canadian cannabis companies tap government funding programs.”

Lamers wrote, “MJBizDaily found that more than 3 million Canadian dollars ($2.2 million) worth of federal funding was provided to almost two dozen companies over the past year, according to the government’s Grants and Contributions portal.”

The second article, published October 3, 2023, reported that “Cannabis-related agricultural businesses based in Alberta are eligible for provincial funding under two programs if they meet certain requirements, the Ministry of Agriculture and Irrigation told MJBizDaily.”

The latest installment, published November 16, 2023, reported that the BC Ministry of Agriculture and Food explained via email that “federally licensed and commercial cannabis production is eligible for many of its programs and services.”

The author wrote, “Federally licensed cannabis producers in British Columbia are eligible to apply for a host of government programs, some of which provide funding, including the provincial portion of the Sustainable Canadian Agricultural Partnership.”

In the News Five Years After Cannabis Legalization in Canada

This month marked the fifth anniversary of the legalization of cannabis in Canada, and news outlets offered various views on the results so far. While some of the articles discussed the challenges and struggles facing the industry, others looked at different aspects.

CTV News reports that “Five years after cannabis legalization, 64 per cent of Canadians are in support of the move.” The article published on the CTV News website was about the results of an online survey conducted by Research Co. “Support for the legalization of marijuana is highest among Canadians aged 55 and over (66 per cent),” Mario Canseco, President of Research Co. said in a press release. “The proportions are lower among those aged 35-to-54 (56 per cent) and those aged 18-to-34 (48 per cent).”


The Canadian Medical Association Journal published “Outcomes associated with nonmedical cannabis legalization policy in Canada: taking stock at the 5-year mark.” This scholarly article reported, “Cannabis legalization in Canada appears not to have been the public health disaster anticipated by some of its opponents, but it cannot be described as a comprehensive or unequivocal success for public health either.”


The Royal Gazette published “Canada and cannabis at Year 5,” which focused on three major aspects: the cannabis market, public health and social justice. “Canadian experience demonstrates there have been problems that must be responded to. But the ending of criminalisation that especially burdened Indigenous and Black people, the creation of a legal market providing untainted cannabis — the strength of which is clear — and the confronting of the illicit one that makes vast sums of money, pays no taxes and has no regard for the quality of what it sells must weigh heavily in the balance.”


What We Heard Report

The federal government released a report that summarizes what a “five-person expert panel has heard over the past year as it engaged with almost 500 stakeholders in nearly 90 meetings across Canada.”

The report, titled “What We Heard,” describes the scope of the engagement and summarizes the responses in several categories including: public health, impact on young persons, impact on First Nations and more.

Read about the expert panel and review here: https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/laws-regulations/cannabis-act-legislative-review/expert-panel/legislative-review-cannabis-act-report.html

Read the report here: https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/laws-regulations/cannabis-act-legislative-review/expert-panel/legislative-review-cannabis-act-report.html

Stratcann summarized the report in an article published on their website on October 10, 2023, the same day the report was released.

Read the Stratcann article here: https://stratcann.com/other/canada-releases-what-we-heard-report-on-the-cannabis-act-review/

Global News followed up the release of the report with an in-depth article on the state of the cannabis industry in Canada. In the feature published on October 16, 2023, Global News offers commentary by several experts including George Smitherman, president and chief executive of the Cannabis Council of Canada.

Read the Global News article here: https://globalnews.ca/news/10027112/cannabis-act-review-canada/

Complete C3 Excise Tax Survey of Licence Holders before Sep 1

Cannabis Council of Canada (C3) is conducting a study on the Canadian cannabis excise tax framework and are looking for input from licensed producers and processors from across the country.

Are you a Health Canada Licence Holder? Please take 10 minutes to fill out an anonymous survey (or forward to your CFO) before September 1st and join C3 August 31st for a virtual discussion with other leaders in the cannabis sector.

“Your input will be invaluable in shaping our conversations with government decision-makers at an upcoming lobby day and in advance of the Fall Economic Statement. All responses are anonymous and will be reported in aggregate.”

Not a licence holder? C3 encourages you to share this survey link with LPs whose operations might be impacted by a change to the excise tax framework.

Use the link below to complete the survey:

Or visit C3 for more information:

Exporting Cannabis to the EU

In a previous post, we discussed how some Canadian producers are selling excess inventory to export markets, including Europe.

In “The Europe Medical Cannabis Market,” Market Data Forecast reports, “The medical cannabis market in Europe is expected to grow from USD 4.96 billion in 2022 to USD 13.37 billion by 2027, growing at a CAGR [compound annual growth rate] of CAGR 21.96% from 2022 to 2027.”

Based on that report, Europe appears to be a significant marketplace for cannabis. But to sell into that market, the exporter must meet the region’s standards. In the case of Europe, those standards include the European Union’s Good Manufacturing Practices, referred to as EU GMP.

In their article, “A Look at Canadian Cannabis Exports,” published in 2021, The Business of Cannabis reported one reason why exports jumped in 2020. “In Canada, more cultivators gained the European Union’s Good Manufacturing Practices (EU GMP) certification, allowing them to export to that continent. More than a dozen Canadian LPs now have EU GMP certified facilities.”

Meeting EU GMP standards is critical for exporting into the European marketplace. But what is EU GMP and how does it differ from the standards Canadian companies already meet?

Health Canada requires that Canadian licensed producers comply with Good Production Practices or GPP standards. If you are a licensed producer in Canada, you are already familiar with GPP. If not, these standards are explained on the Health Canada website.

Essentially, GPP requires that cannabis businesses have appropriate procedures for all activities related to producing a product that is safe for public consumption. GPP mandates that systems be in place to ensure quality and traceability.

Good Manufacturing Practices, GMP, takes GPP further including requiring more stringent testing.

The Foundation of Cannabis Unified Standards (FOCUS) states, “GMP is the proactive part of quality assurance. It is designed to minimize the risks involved in all steps of the manufacturing process. A basic tenant of GMP is that quality cannot be tested into a product. It must be built into each batch of product during all stages of the manufacturing process.”

Originally designed for pharmaceutical products, GMP can be applied to any production process and is a requirement for those wishing to market medical cannabis in Europe.

The EU GMP standards are complex, and the information can be difficult to navigate, especially how it applies to cannabis.

But the Canadian government has published guidelines designed to help manufacturers meet GMP standards. Their guidance document has been written “with a view to harmonize with GMP standards from: the World Health Organization (WHO); the Pharmaceutical Inspection Cooperation/Scheme (PIC/S); the International Council on Harmonisation (ICH); the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH); other regulatory agencies in other countries.”

While the EU is not mentioned specifically, these Canadian standards are a good starting point for cannabis companies considering exporting into other markets. These guidelines will help producers understand what is required and can be used as a stepping stone toward EU GMP certification.

According to the media, the EU standards are stringent, and certification can be time consuming and costly. But with a market as large as Europe, Canadian companies are in a position to benefit from the opportunities that an EU GMP certificate can offer.

Can Canadian Producers Export Excess Supply?

With media reporting oversupply challenges in the Canadian cannabis industry, can producers turn to export markets to sell their inventory? The answer might be yes. As countries around the world legalize cannabis, new opportunities are emerging for producers in Canada.

Canadian companies have been exporting cannabis for several years already. In fact, back in June 2020, MJBizDaily published a two-part article on Canada’s export of medical cannabis during 2019. Part 1 was titled, “Canada exported record amount of dried cannabis in 2019…” Part 2 reported, “Canadian exports of medical cannabis oil jumped fivefold in 2019.”

Canadian Regulatory Review reported in September of 2020 that the Canadian government had even become supportive of cannabis exports. “On the export side, and to further bolster trade, as of January 2020, the federal government through Canada’s Trade Commissioner Service extended trade commissioner services for Canadian cannabis companies exporting cannabis for medical and scientific purposes.”

A few months after that article, in April 2021, Prohibition Partners released a report called “Revealed: The Canadian Cannabis Export Market for 2020.” The report notes that the largest export markets for Canada at the time were Germany, Australia, Israel and the United Kingdom. “…new data shows a huge increase in the exports of cannabis from the country in 2020, as well as a changing network of countries that are importing from established producers in Canada.”

In May of that same year, Business of Cannabis took “A look at Canadian cannabis exports,” noting that “Dried cannabis flower and cannabis oil exports more than doubled in 2020, while imports dropped to virtually zero…”

An article titled, “How Canada’s Oversupply of Cannabis Is an Export Opportunity,” was published in October of 2022 by Canadian Cannabis Exchange. “As the demand for cannabis legalization increases internationally, Canada has the opportunity to become the world leader in cannabis exports… The European Union is proving to be a lucrative market for Canadian exports.”

Stratcann: Micros Could Surpass Standards in Canada Next Year

According to an article published by Stratcann, “At the current pace of licensing, the total number of micro licences could surpass standard licences in 2024.”

Stratcann, an online news publication covering the evolution of the legal cannabis industry in Canada and around the world, reported that “Micro cannabis licences continue to grow in popularity in Canada, at almost 42 percent of all licences issued as of March 31, 2023. Just over half (51 percent) of licences were standard, three percent were nursery licences, and nearly four percent were medical-sales only licences.”

Report: Medical Cannabis Access and Experiences in Canada

The Medical Cannabis Access Survey Summary Report, issued in April of 2023, provides an in-depth view of individuals currently taking medical cannabis in Canada and their access experiences.

Topics covered by the report include:

  • Changes in Medical Cannabis Use Since Implementation of the Cannabis Act
  • Retention of the Medical Cannabis Program and Needed Improvements
  • Perceived Improvements to the Medical Cannabis Program

This report was formulated from results drawn from the Medical Cannabis Access Survey, which received ethical approval from the University of Manitoba Research Ethics Board 1 and McGill University Research Ethics Office of the Faculty of Medicine and Health Sciences.

For more information and to download a copy of the summary report, visit: https://www.medicalcannabissurvey.ca/report

The European Cannabis Report for 2023

Published by Prohibition Partners, The European Cannabis Report: 8th Edition, 2023, provides the latest information and analysis on the development of the cannabis markets across Europe.

“Included in the report are deep dives into all key sectors and geographic regions in the European cannabis industry, with many data sources which have been exclusively obtained by Prohibition Partners, or else remain un-reported to date.”

For more information, including how to download a free copy of the report, visit:

Health Canada Seeks Your Feedback from March 25 to May 24, 2023

In relation to a consultation on potential amendments to the Cannabis Regulations, Health Canada is seeking feedback and comments on potential amendments to the Cannabis Regulations.

The aims of the consultation include clarifying existing requirements, eliminating regulation inefficiencies and duplications and reducing administrative and regulatory burdens, and Health Canada is seeking input from:

  • cannabis industry stakeholders
  • public health stakeholders, non-governmental organizations
  • researchers and research or academic institutions
  • First Nations, Inuit and Métis partners and organizations
  • law enforcement
  • provincial, territorial and municipal governments

For more information including how you can provide feedback until May 24, 2023, visit:

Congratulations Headstone Finalist in 2023 Canadian Cannabis Championship

On March 21, 2023, the Canadian Cannabis Championship named 13 Flower Finalists — and AirMed client Headstone Cannabis has made the list.

The CCC competition is being held in conjunction with the Grow Up Conference & Expo happening May 28-29, 2023 in Edmonton, Alberta.

“The top flower finalists include industry leaders such as Great Gardener Farms, Truth Holdings, Distinkt Cannabis, Headstone Cannabis, Stewart Farms, North 40 Cannabis, JustFire, Black Rock Cannabis, Palm Gardens, Northside Grow Co., Origine Nature, Vertical 7, and Into the Weeds.”

Judging will take place at the conference on May 28 with winners announced live on Tuesday, May 30.

For more about the Canadian Cannabis Championship, click here: https://canadiancannabischampionship.com/2023-finalists/

For more about Grow Up, click here: https://growupconference.com/

For more about Headstone Cannabis, click here: https://headstonecannabis.com/

Canadian Cannabis: State of the Industry Report

The industry analysts at Ernst & Young have published a state of the industry report for the Canadian cannabis industry. Covering until the end of 2022, this report was “intended to highlight the key issues facing the cannabis industry and provide the supporting evidence.”

The executive summary highlights:
1. Successes of legalization;
2. Key issues facing the industry;
3. Key implications and takeaways, and
4. Future policy considerations

The methodology used to create the report including secondary and primary research to identify high-level successes and issues since inception of the Cannabis Act.

Read about Great White North Growers in Cannabis Prospect Magazine

AirMed client, Great White North Growers, has been profiled in a feature article in the December 2022 edition of Cannabis Prospect magazine.

The article, titled “The French Connection: How Great White North Growers Became Synonymous with Quebec Cannabis” features an interview with company co-founder George Goulakos.

The author writes, “In a few short years, Great White North Growers has gone from a licensed producer of its house brand and 514 Cannabis to a powerhouse working with over 30 growers in the province to get its products in SDQC stores.”

In the interview, Goulakos describes his company’s history, business model and future plans. “My partner Peter Schissler and I realized that there was a fantastic opportunity in this exciting new industry, and we decided to get in early… We were one of the first Licensed Producers in Quebec to be granted all Health Canada licenses and saw an opportunity to assist Quebec-based micro cultivators bring their products to market… Our mission is to be a proud Canadian company with strong values and a social conscience.”

To read the full article visit: https://issuu.com/cannabisprospectmag/docs/cannabis_prospect_magazine_dec._22_issue_-_digi/10

For more information on Great White North Growers, visit: https://gwng.ca/

Cannabis Prospect Magazine is Canada’s premier trade publication for cannabis industry professionals. Cannabis Prospect Magazine showcases the people and companies forging this new industry with articles written by industry experts and advisors that make up this new and dynamic marketplace. For more information visit: https://cannabisproonline.com/

Read about AirMed client Rogue Processing at Stratcann

AirMed client Rogue Processing has been profiled on Canada’s legal cannabis news platform, StratCann.

The article features Graham Taylor, the President and CEO of Rogue Processing, which is located in Niverville, Manitoba, about 20 km south of Winnipeg. Rogue offers state-of-the-art co-packing services to Canadian cannabis companies looking for a client-focused, eco-friendly, cost-effective, and tech-savvy alternative to current service providers.

“It’s sustainable not only because we’re using more environmentally friendly packaging, it’s also a more financially sustainable model where customers keep more profits in their pocket allowing them to…grow their business.” Graham Taylor

Stratcann covers the evolution of the legal cannabis industry in Canada and around the world, publishes news, company features and brand profiles.

To read the full Rogue Processing profile on the Stratcann website visit:

For more information on Rogue Processing, visit: https://rogueprocessing.com/

Research Predicts International Cannabis Market Increases Across Globe

A new research report forecasts increases over 2021 cannabis sales from 16 percent in Europe and 22 percent in Asia to 45 percent in Latin America.

The report titled “International Cannabis Refresh: The impact of shifting global regulatory environments” was published in October 2022 by the Brightfield Group.

The researchers state that growth in Europe “can largely be attributed to the commencement of adult-use sales, both in trial programs and in formal regulation…” But they also say that domestic cultivation could boost market sizes, “with many countries currently relying on imports from other nations.”

The Asia Pacific & Middle East region shows even higher forecasted increases over 2021 – as much as 22 percent. Israel has the largest market with Australia in second place.

In Latin America, cannabis sales are expected to increase by as much as 45 percent over 2021. This is attributed to the expectation that Mexico and Costa Rica will enter the marketplace by 2025.

The publishers of this report, Brightfield Group, is a research firm specializing in emerging categories including CBD, cannabis, and wellness.

For more information visit: Brightfield Group.

What to Expect from the Cannabis Act Review

Since the announcement of the Cannabis Act review, people are speaking out about what they hope to see from reviewers.

The review was initially planned to begin in 2021 and look at the public health implications of the legalization of cannabis in Canada.

The CBC reported that the government delayed the start of the review to expand the scope. “The review mandate has been expanded to include an examination of the social and environmental effects of the Cannabis Act, the impact of legalization and regulation of medical cannabis and the impact on racialized communities and women.”

Read more here: https://www.cbc.ca/news/politics/public-health-cannabis-mandated-eview-1.6591442

An article in The Globe & Mail stated that “For George Smitherman, the chief executive officer of the Cannabis Council of Canada, the national industry association, the announcement comes at a critical time. Companies continue to face pressure from the illicit market, as well as excise taxes, provincial distributor markups and regulatory fees.”

Read more here: https://www.theglobeandmail.com/business/article-health-canada-cannabis-act-review/

The Toronto Star notes that the pot sector wants packaging changes and financial relief from the review. “The industry is frustrated the review’s launch arrived a year later than mandated but is still hoping it can result in enough tweaked restrictions to make cannabis distribution easier, draw in new customers and prevent more staffing and facility cuts.”

Read more here: https://www.thestar.com/news/cannabis/2022/09/22/pot-sector-wants-packaging-changes-financial-relief-from-cannabis-act-review.html

The review is expected to be completed in 18 months, and government officials say that it will consider health issues as well as financial, tax, regulatory and criminal-justice matters.